Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
Exelixis will present new data on its flagship product CABOMETYX and investigational agent zanzalintinib at the 2026 ASCO Annual Meeting. The presentations will cover findings in various cancer types, including neuroendocrine tumors, kidney cancer, and advanced colorectal cancer. These studies aim to reinforce CABOMETYX's role and accelerate zanzalintinib's development, demonstrating Exelixis's commitment to improving cancer patient care.
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
Exelixis, Inc. (Nasdaq: EXEL) announced presentations for its flagship product, CABOMETYX (cabozantinib), and its investigational oral kinase inhibitor, zanzalintinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will highlight new analyses from the phase 3 CABINET pivotal trial and findings from the phase 3 STELLAR-303 trial, showcasing progress in various tumor types including neuroendocrine tumors, kidney cancer, and advanced colorectal cancer. The company aims to build upon CABOMETYX's therapeutic profile and accelerate the development of zanzalintinib.
How Investors May Respond To Exelixis (EXEL) Merck MRD+ Colorectal Cancer Trial Collaboration
Exelixis recently announced a clinical development collaboration with Merck for the STELLAR-316 trial, testing zanzalintinib with KEYTRUDA QLEX in MRD+ colorectal cancer patients. This partnership aims to diversify Exelixis's revenue beyond CABOMETYX and strengthens the investment narrative, though concerns about CABOMETYX concentration and discount pressure remain. The article suggests investors should consider the broader potential of zanzalintinib, including its FDA review in metastatic colorectal cancer, against more pessimistic analyst forecasts.
Is Exelixis Stock Utilizing Systematic Share Retirement for Long-Term Alpha?
Exelixis (EXEL) is highlighted as a "Capital Compounder" due to its systematic share count reduction, having decreased shares outstanding by 7.3% in the last year. This strategy has led to a significant increase in earnings per share and strong stock appreciation, returning 152% in three years. The company's high operating margins and substantial net cash position enable consistent share buybacks, providing a durable engine for shareholder returns independent of short-term market fluctuations.
EXEL (EXEL) Rule 144 filing: 32,110 issuer-held shares vested
EXELIXIS, INC. (EXEL) has filed a Rule 144 notice indicating that 32,110 issuer-held shares of common stock have vested under a registered plan. These shares vested on May 15, 2026, across four different lots, with the filing recorded on May 20, 2026. This filing is categorized as neutral in its impact and sentiment, as it reflects routine vesting events rather than open-market insider sales.
EXEL: Zanzalintinib targets leadership in CRC and RCC with pivotal trials and robust clinical strategy
Exelixis's drug, Zanzalintinib, is progressing through pivotal trials for colorectal cancer (CRC) and renal cell carcinoma (RCC) with the goal of setting new standards of care. The company, Exelixis, Inc. (EXEL), is focusing on biotherapeutics, employing a disciplined strategy for prioritizing and disclosing data. This strategy was detailed during the Stifel 2026 Targeted Oncology Virtual Forum.
Exelixis (NASDAQ: EXEL) CEO reports share gifts and tax withholding
Exelixis CEO Michael Morrissey reported non-market dispositions of company shares including tax withholding and bona fide gifts. On May 15, 2026, 128,497 shares were withheld for taxes related to vesting restricted stock units. On May 18, 2026, he gifted a total of 248,094 shares through two separate transactions to the Morrissey Family Living Trust.
Exelixis Insider Sold Shares Worth $1,745,050, According to a Recent SEC Filing
An insider at Exelixis sold shares valued at $1,745,050, according to a recent SEC filing. The article also briefly mentions Unity Software's fourth-quarter financial results, reporting a revenue increase to $609 million and a quarterly loss of 66 cents per share. The full details of the Exelixis insider transaction are likely behind a login wall.
Exelixis SVP Brenda Hefti sells $332,641 in stock
Brenda Hefti, Senior Vice President and General Counsel at Exelixis, Inc., sold shares totaling $332,641 on May 18, 2026, and disposed of additional shares to cover tax obligations on May 15, 2026. These transactions were executed under a Rule 10b5-1 trading plan. Following these sales, Ms. Hefti directly holds over 100,000 shares of Exelixis common stock and indirectly holds additional shares through the company's 401(k) Plan.
Exelixis (NASDAQ: EXEL) EVP Dana Aftab reports tax-withholding of 30,578 shares
Exelixis EVP Dana Aftab reported a routine tax-withholding disposition of 30,578 shares of common stock at $51.10 per share. This transaction was to cover taxes related to the vesting of previously granted restricted stock units, and not an open-market sale. Following this, Aftab directly holds 638,192 shares and an additional 5,835 shares indirectly through a 401(k) plan.
Exelixis Insider Sold Shares Worth $1,745,050, According to a Recent SEC Filing
An insider at Exelixis, Inc. (EXEL) sold shares valued at $1,745,050, as detailed in a recent SEC filing. This transaction was reported by MT Newswires on May 20, 2026. Exelixis is an oncology company known for its marketed pharmaceutical products like cabozantinib and its lead investigational asset, zanzalintinib.
Exelixis EVP and CFO Senner sells $1.75m in company stock
Christopher J. Senner, EVP and CFO of Exelixis, Inc. (NASDAQ:EXEL), sold 34,901 shares of company stock for $1.75 million on May 18, 2026. This sale occurred while the stock is near its 52-week high, although InvestingPro analysis suggests it remains undervalued. Senner also had shares withheld for tax obligations related to vested restricted stock units.
Exelixis EVP and CFO Senner sells $1.75m in company stock
Christopher J. Senner, EVP and CFO of Exelixis, sold 34,901 shares of company stock for $1.75 million, with the stock trading near its 52-week high, although InvestingPro analysis indicates it remains undervalued. This transaction follows the withholding of 40,892 shares to cover tax obligations from vested restricted stock units. Exelixis has also reported strong Q1 2026 financial results and entered a clinical collaboration with Merck for a phase 3 trial.
Exelixis (EXEL) EVP reports 33,265-share tax withholding, 389,748-share stake
Exelixis (EXEL) EVP, Commercial, Patrick J. Haley, reported a tax-related share withholding of 33,265 common stock shares at $51.10 each to cover tax obligations from vested Restricted Stock Units (RSUs). Following this transaction, Haley now holds 389,748 shares of Exelixis common stock. This total includes shares pending RSU and performance-based RSU vesting, as well as shares acquired through the Employee Stock Purchase Plan.
Exelixis (NASDAQ: EXEL) CFO sells shares, reports tax withholding and large remaining stake
Exelixis, Inc. EVP and CFO Christopher J. Senner sold 34,901 shares of common stock in an open-market transaction at a weighted average price of $50.00. Additionally, 40,892 shares were withheld by the company to cover taxes on vesting restricted stock units at $51.10 per share. Following these transactions, Senner retains a substantial stake, holding 952,317 shares directly and 2,723 indirectly, with another 403,915 shares subject to unvested awards.
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
Exelixis has entered a clinical development collaboration with Merck for the Phase 3 STELLAR-316 pivotal trial, which will evaluate zanzalintinib with and without KEYTRUDA QLEX in patients with resected stage II/III colorectal cancer. Merck will supply KEYTRUDA QLEX for the trial, which aims to prevent or delay metastatic progression in MRD+ patients. Exelixis plans to initiate the trial in mid-2026, leveraging Natera's Signatera™ assay to identify eligible patients.
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
Exelixis has announced a clinical development collaboration with Merck for the STELLAR-316 Phase 3 pivotal trial. This trial will evaluate zanzalintinib in combination with Merck's KEYTRUDA QLEX™ for patients with resected stage II/III colorectal cancer. Under the agreement, Exelixis will sponsor the trial while Merck supplies KEYTRUDA QLEX™, aiming to potentially prevent or delay metastatic progression in this high-risk patient population.
Proposed resale of vested restricted shares by EXEL (NASDAQ: EXEL)
Morgan Stanley Smith Barney LLC Executive Financial Services has filed a Form 144 notice for the proposed sale of vested restricted Common Stock from Exelixis, Inc. (NASDAQ: EXEL). The filing details four separate parcels of shares totaling 9,454, 9,833, 8,748, and 6,866, all vesting under a registered plan on May 15, 2026. This is a routine regulatory filing indicating an upcoming resale of shares, with no immediate impact on their market value.
[144] EXELIXIS, INC. SEC Filing
This SEC filing ([144] EXELIXIS, INC. SEC Filing) for Exelixis, Inc. (EXEL) details a proposed sale of securities under Rule 144. The filing indicates a sale of 6,625 common shares with an aggregate market value of $332,641.25, acquired on May 15, 2026, as restricted stock from the issuer. Morgan Stanley Smith Barney LLC is listed as the broker for the transaction, which is scheduled for May 18, 2026, on NASDAQ.
Stephens Investment Management Group LLC Buys 28,265 Shares of Exelixis, Inc. $EXEL
Stephens Investment Management Group LLC increased its stake in Exelixis, Inc. by 1.1% in the fourth quarter, acquiring an additional 28,265 shares to reach a total of 2.54 million shares valued at $111.3 million. This strategic move makes Exelixis the 4th biggest position in the firm's investment portfolio, representing about 1.4%. The report also highlights recent insider selling, strong quarterly earnings beating estimates, and analysts maintaining a "Hold" rating with an average target price of $47.35 for the biotechnology company.
Thrivent Financial for Lutherans Increases Holdings in Exelixis, Inc. $EXEL
Thrivent Financial for Lutherans significantly increased its stake in Exelixis, Inc. by 1,821% in the fourth quarter, now owning over 1.1 million shares. This comes as Exelixis reported strong first-quarter earnings, beating analyst estimates for both EPS and revenue. Despite the positive earnings, the stock saw a slight dip, and analysts maintain a "Hold" consensus rating with a mixed outlook.
48,292 Shares in Exelixis, Inc. $EXEL Purchased by Convergence Investment Partners LLC
Convergence Investment Partners LLC recently acquired 48,292 shares of Exelixis, Inc., valued at approximately $2.12 million, establishing a new position in the biotechnology company. This purchase comes as Exelixis reported strong first-quarter earnings, surpassing analyst estimates for both EPS and revenue. Despite notable insider selling and institutional ownership already at 85.27%, analysts currently maintain a "Hold" consensus rating with a price target of $47.35.
Exelixis stock (US30161Q1040): New data and pipeline catalysts in focus
Exelixis stock is attracting investor attention due to its established oncology product, Cabometyx, and its ongoing pipeline developments. The company's focus on cancer treatments, particularly kidney and liver cancer, positions it within a closely watched sector for U.S. biotech investors. The article highlights that key catalysts for the stock include clinical data readouts, regulatory updates, and revenue trends, emphasizing the importance of both commercial stability and pipeline progress in driving investor sentiment.
EXEL (NASDAQ: EXEL) trustee files to sell 100,000 shares valued at $5.09M
An affiliate of EXEL (Exelixis, Inc.), the Michael Morrissey/Morrisey Family Trust, has filed a Form 144 to sell 100,000 shares of common stock, valued at $5.09 million. The shares were received as a Gift from Affiliate on November 11, 2025, with an earlier acquisition date of November 15, 2020. The filing, dated May 14, 2026, indicates a neutral impact and sentiment for the proposed sale.
Exelixis Insider Sold Shares Worth $373,646, According to a Recent SEC Filing
An insider at Exelixis sold shares worth $373,646, as reported in a recent SEC filing. The transaction involved director Vincent Marchesi selling 15,000 shares at an average price of $24.91 each. This sale follows previous insider buying and selling activities over the past year, with insiders selling 1,894,868 shares and buying 10,000 shares in total.
Exelixis stock hits 52-week high at 49.63 USD By Investing.com
Exelixis Inc. (EXEL) stock reached a new 52-week high of $49.63, reflecting a 33% increase over the past year and a 9% gain in the last week. This surge is attributed to strong market performance, positive developments in its drug pipeline, and robust Q1 2026 financial results that exceeded expectations. InvestingPro analysis suggests the stock is currently undervalued, with a P/E ratio of 15.93 and a PEG ratio of 0.4.
Exelixis Insider Sold Shares Worth $2,742,600, According to a Recent SEC Filing
An insider at Exelixis recently sold 90,000 shares of the company's stock for a total value of $2,742,600. This transaction was disclosed in a Form 4 filing with the SEC. Following the sale, the insider still directly owns 75,541 shares of Exelixis stock.
Exelixis stock hits 52-week high at 49.63 USD
Exelixis Inc. (EXEL) stock reached a new 52-week high of $49.63, reflecting a 33% increase over the past year and a 9% gain in the last week. This surge is attributed to strong investor confidence, positive pipeline developments, and robust Q1 2026 financial results that surpassed expectations for both earnings and revenue. InvestingPro analysis suggests the stock is undervalued, with analysts revising earnings estimates upward.
Exelixis Insider Sold Shares Worth $949,164, According to a Recent SEC Filing
An insider at Exelixis sold shares valued at $949,164, as disclosed in a recent SEC filing. This transaction follows other recent insider share sales from the oncology company. Exelixis specializes in oncology, with its flagship molecule cabozantinib being a key product and zanzalintinib as a lead investigational asset.
Number of shareholders of Exelixis, Inc. – NASDAQ:EXEL
The article provides a title indicating it will cover the number of shareholders for Exelixis, Inc. (NASDAQ: EXEL). It appears to be a stub or an incomplete data output from TradingView, lacking the actual shareholder count but showing the context within the financial platform. The content primarily consists of navigation, disclaimers, and product links from the TradingView website.
Director at Exelixis (NASDAQ: EXEL) sells 60,000 shares in trade
Exelixis director George Poste sold 60,000 shares of common stock on May 7, 2026, at a weighted average price of $45.71 per share, totaling $2.74 million. Following the sale, Poste directly retains 118,832 shares, which includes 9,812 shares from restricted stock units. This transaction was reported via a Form 4 SEC filing, detailing the open-market sale activity.
EXEL SEC Filings - Exelixis Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Exelixis' (EXEL) official regulatory disclosures, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It highlights how Exelixis, an oncology-focused biopharmaceutical company, uses these filings to report financial results, corporate actions, and leadership changes. The platform also offers AI-powered summaries to help investors quickly understand key points and implications of these complex documents.
Exelixis (EXEL) director exercises options and sells 20,634 shares at $46
Exelixis director Maria C. Freire exercised options to acquire 20,634 shares of common stock at $19.77 per share and subsequently sold all of them in an open-market transaction at $46.00 per share on May 7, 2026. After these transactions, her direct holdings in Exelixis amount to 100,819 shares, which include 9,812 shares from unvested restricted stock units. The exercised option had been fully exercisable since May 23, 2019.
Exelixis (NASDAQ: EXEL) CEO gifts 109,676 shares to Bombora Rise Foundation
Exelixis CEO Michael Morrissey gifted 109,676 shares of company stock to the Bombora Rise Foundation through the Morrissey Family Living Trust on May 6, 2026. This benevolent act, considered a bona fide charitable transfer, was reported in an SEC Form 4 filing which also updated his remaining holdings. After the gift, the trust still holds 1,880,280 indirect shares, alongside additional shares tied to RSUs and a 401(k) plan.
Exelixis (EXEL) Margin Expansion To 35.1% Challenges Bearish Pricing Narratives
Exelixis (EXEL) reported strong Q1 2026 results with revenue of US$610.8 million and basic EPS of US$0.81, leading to a significant expansion in its net profit margin to 35.1%. This performance challenges bearish concerns about pricing pressures and reliance on cabozantinib, with the company’s five-year earnings growth at 37.6% per year. While the valuation metrics suggest the stock is undervalued compared to peers and its DCF fair value, investors are weighing this against more moderate future growth forecasts.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May 2026
Exelixis, Inc. announced that its management will participate in multiple investor conferences in May 2026, including the BofA Securities Health Care Conference, RBC Capital Markets Global Healthcare Conference, Stifel Virtual Targeted Oncology Forum, and Bernstein's 42nd Annual Strategic Decisions Conference. These fireside chats will be webcast on the company's website, with replays available for at least 30 days. Exelixis is an oncology company focused on developing next-generation cancer treatments.
Exelixis to Present at Healthcare Conferences in May 2026
Exelixis, Inc. will be participating in two investor conferences in May 2026, offering live webcasts of their fireside chats. The biotechnology company's management will speak at the BofA Securities 2026 Healthcare Conference on May 12th and the Goldman Sachs 47th Annual Global Healthcare Conference on May 13th. These events will be accessible to the public through the "Investors & Media" section of the Exelixis website.
[144] EXELIXIS, INC. SEC Filing
This SEC filing for Exelixis, Inc. (EXEL) is a Form 144, indicating a proposed sale of securities under Rule 144 of the Securities Act of 1933. The filing details the sale of 20,634 shares of common stock with an aggregate market value of $949,164.00, acquired on May 7, 2026, through the exercise of options. The shares are to be sold via Morgan Stanley Smith Barney LLC on NASDAQ.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
Exelixis, Inc. announced that its management will participate in multiple investor conferences in May, including the BofA Securities Health Care Conference, RBC Capital Markets Global Healthcare Conference, Stifel Virtual Targeted Oncology Forum, and Bernstein's 42nd Annual Strategic Decisions Conference. The company will host fireside chats at these events, with webcasts and replays available on its investor relations website. Exelixis is an oncology company focused on developing next-generation cancer treatments.
Exelixis, Inc. (NASDAQ:EXEL) Q1 2026 Earnings Call Transcript
Exelixis, Inc. reported strong Q1 2026 financial results, with net product revenues for their CABOMETYX franchise growing 8% year-over-year to $555 million, and global revenues up 12.5% to $764 million. The company is advancing zanzalintinib (ZANZA) as its next potential oncology franchise, with an NDA under review for colorectal cancer and seven pivotal trials ongoing or soon to start. Exelixis also reiterated its full-year 2026 financial guidance and announced a new $50 million stock repurchase plan.
Margin Gains From Oncology Portfolio Might Change The Case For Investing In Exelixis (EXEL)
Exelixis, Inc. reported strong first-quarter 2026 results, with significant revenue and net income growth driven by operational efficiency in its oncology portfolio. This performance supports short-term earnings but investors are also focused on the regulatory progress of zanzalintinib, which could reduce reliance on CABOMETYX, and the potential impact of increasing 340B sales discounts on future margins. Analysts have diverging views on the stock's future, highlighting the need for investors to consider both current profitability and long-term pipeline diversification.
Earnings Flash (EXEL) Exelixis, Inc. Posts Q1 Adjusted EPS $0.87 per Share, Vs. FactSet Est of $0.76
Exelixis, Inc. (EXEL) announced its Q1 adjusted EPS of $0.87 per share, surpassing the FactSet estimate of $0.76 per share. This indicates a stronger financial performance than anticipated by analysts for the quarter.
Exelixis Q1 2026 slides: revenue grows 10%, zanzalintinib advances
Exelixis reported strong first-quarter 2026 financial results with total revenues growing 10% year-over-year to $610.8 million and non-GAAP diluted EPS of $0.87, exceeding analyst expectations. The company highlighted the continued commercial strength of its CABOMETYX franchise and the significant advancement of its zanzalintinib pipeline, with seven pivotal trials underway and an FDA decision anticipated in December 2026 for metastatic colorectal cancer. Exelixis also demonstrated a commitment to shareholder returns through aggressive stock repurchases while reaffirming its full-year 2026 financial guidance.
Exelixis, Inc. Reports Climb In Q1 Profit
Exelixis, Inc. (EXEL) reported a significant increase in its first-quarter profit, with earnings totaling $210.47 million, or $0.79 per share, up from $159.62 million, or $0.55 per share, in the prior year. Excluding certain items, adjusted earnings were $232.76 million, or $0.87 per share. The company's revenue also saw a 10.0% rise to $610.81 million from $555.45 million year-over-year, and full-year revenue guidance is set between $2.525 billion and $2.625 billion.
Transcript : Exelixis, Inc., Q1 2026 Earnings Call, May 05, 2026
This article provides the transcript for Exelixis, Inc.'s Q1 2026 Earnings Call, held on May 5, 2026. During the call, the company announced its full-year 2026 revenue guidance to be between $2.53 billion and $2.63 billion, aligning with FactSet's estimate. The earnings call also covered various financial highlights and updates from Exelixis, including Q1 non-GAAP earnings and revenue increases, and reported adjusted EPS of $0.87 per share.
Exelixis Posts Strong Q1 Results, Expands Share Buybacks
Exelixis announced strong first-quarter 2026 results, with revenue up to $610.8 million, driven by cabozantinib sales and collaboration income. The company also reported an increase in GAAP net income and non-GAAP diluted EPS, partially due to ongoing share buybacks. Exelixis maintained its 2026 financial guidance and authorized an additional $750 million stock repurchase program, reflecting confidence in its financial performance and long-term strategy.
Exelixis (EXEL) Q1 2026 Earnings Transcript
Exelixis (NASDAQ:EXEL) reported strong Q1 2026 financial results, with total revenues of $611 million and a substantial increase in its cabozantinib franchise net product revenues, driven by record patient starts for CABOMETYX. The company highlighted CABOMETYX's continued leadership in renal cell carcinoma (RCC) and neuroendocrine tumors (NETs) while enthusiastically advancing its ZANZA pipeline, particularly with the NDA for ZANZA plus atezolizumab in colorectal cancer under review. Management reiterated full-year 2026 financial guidance and demonstrated a commitment to shareholder returns through significant share repurchase activity, emphasizing their belief in the company's undervaluation and future growth prospects.
Earnings Flash (EXEL) Exelixis, Inc. Posts Q1 Adjusted EPS $0.87 per Share, vs. FactSet Est of $0.76
Exelixis, Inc. (EXEL) reported its Q1 adjusted EPS at $0.87 per share, surpassing the FactSet estimate of $0.76. The company also announced an expected full-year 2026 revenue range of $2.53B - $2.63B, against a FactSet estimate of $2.58B. This news highlights a strong first quarter performance for the oncology company, exceeding analyst expectations for earnings.
Earnings Flash (EXEL) Exelixis, Inc. Reports Q1 Revenue $610.8M, vs. FactSet Est of $607.5M
Exelixis, Inc. (EXEL) reported Q1 revenue of $610.8 million, surpassing the FactSet estimate of $607.5 million. The company also expects its full-year 2026 revenue to be in the range of $2.53 billion to $2.63 billion, compared to the FactSet estimate of $2.58 billion. Exelixis is an oncology company with four marketed pharmaceutical products, including cabozantinib formulations CABOMETYX and COMETRIQ.
Exelixis: Q1 Earnings Snapshot
Exelixis Inc. reported first-quarter earnings of $210.5 million, or 79 cents per share, which adjusted to 87 cents per share, surpassing Wall Street expectations. The drug developer's revenue of $610.8 million fell short of forecasts, though the company projects full-year revenue between $2.53 billion and $2.63 billion.
